BioCrine stock

BioCrine has raised a total of SEK 112 million in capital, according to our records. The amount raised in each funding round is shown once you create an account.

In its latest share issue, in August 2026, BioCrine was valued at SEK 189 million post-money. The price was SEK 600 per share.

The largest shareholders in BioCrine are Bengt Lars Olov Spånberg (9.83 %), Per-Olof Berggren (9.54 %), and Svipdag AB (4.99 %). The figures come from Eivora and were last updated in December 2025.

The CEO of BioCrine is Per-Olof Berggren. The board is chaired by Kenth Ingemar Petersson.

BioCrine is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.

Yes, it is possible to buy existing shares in BioCrine through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.

Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.

Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.

The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.

No, BioCrine is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.

Yes. Shares in BioCrine can be delivered to an ordinary securities account with a broker such as Avanza or Nordnet, and are registered as the transaction completes.

Yes. The articles of association carry transfer restrictions, giving existing shareholders the right to take over the shares ahead of an outside buyer. Expect the transfer to take around 30 days longer while that runs its course.